+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Disease Vaccine Market Research Report by Infection (Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis), by Type (Bacterial Vaccine, Combination Vaccine, and Viral Vaccine), by Age Group - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 5012997
  • Report
  • July 2020
  • Region: Global
  • 202 pages
  • 360iResearch™
UP TO OFF
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Respiratory Disease Vaccine Market to Grow USD 25,236.13 Million by 2025, at a CAGR of 4.80%

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
The Global Respiratory Disease Vaccine Market is expected to grow from USD 19,048.08 Million in 2019 to USD 25,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.80%.

Market Segmentation & Coverage:

This research report categorizes the Respiratory Disease Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:

The Streptococcus Pneumoniae is projected to witness the highest growth during the forecast period

Based on Infection, the Respiratory Disease Vaccine Market studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis. The Influenza Virus commanded the largest size in the Respiratory Disease Vaccine Market in 2019. On the other hand, the Streptococcus Pneumoniae is expected to grow at the fastest CAGR during the forecast period.

The Combination Vaccine is projected to witness the highest growth during the forecast period

Based on Type, the Respiratory Disease Vaccine Market studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine. The Viral Vaccine commanded the largest size in the Respiratory Disease Vaccine Market in 2019. On the other hand, the Combination Vaccine is expected to grow at the fastest CAGR during the forecast period.

The Adult Vaccination is projected to witness the highest growth during the forecast period

Based on Age Group, the Respiratory Disease Vaccine Market studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination. The Infant Vaccination commanded the largest size in the Respiratory Disease Vaccine Market in 2019. On the other hand, the Adult Vaccination is expected to grow at the fastest CAGR during the forecast period.

The Asia-Pacific is projected to witness the highest growth during the forecast period

Based on Geography, the Respiratory Disease Vaccine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Respiratory Disease Vaccine Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Respiratory Disease Vaccine Market including AstraZeneca, Bavarian Nordic, Bayer AG, Bio Farma, Dynavax Technologies Corporation, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., and Serum institute of India Private Limited.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Respiratory Disease Vaccine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Disease Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Disease Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Disease Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Respiratory Disease Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Respiratory Disease Vaccine Market?
6. What are the modes and strategic moves considered suitable for entering the Global Respiratory Disease Vaccine Market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary
3.1. Market Outlook
3.2. Infection Outlook
3.3. Type Outlook
3.4. Age Group Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing prevalence of respiratory disorders
5.2.2. Clinical trials and vaccines developments in pipeline
5.2.3. Government initiatives supporting respiratory health
5.3. Restraints
5.3.1. Lack of inadequate delivery infrastructure & limited awareness
5.4. Opportunities
5.4.1. Increasing R&D expenditure by leading companies
5.4.2. Increase vaccine availability through reselling collaborations
5.5. Challenges
5.5.1. Consumer trust & confidence in respiratory disease vaccination

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations
6.3.1. COVID: Eye on Proactive Vaccine Development

7. Global Respiratory Disease Vaccine Market, By Infection
7.1. Introduction
7.2. Influenza Virus
7.3. Pertussis
7.4. Streptococcus Pneumoniae
7.5. Tuberculosis

8. Global Respiratory Disease Vaccine Market, By Type
8.1. Introduction
8.2. Bacterial Vaccine
8.3. Combination Vaccine
8.4. Viral Vaccine

9. Global Respiratory Disease Vaccine Market, By Age Group
9.1. Introduction
9.2. Adolescent Vaccination
9.3. Adult Vaccination
9.4. Infant Vaccination

10. Global Respiratory Disease Vaccine Market, By Geography
10.1. Introduction
10.2. Americas
10.2.1. Argentina
10.2.2. Brazil
10.2.3. Canada
10.2.4. Mexico
10.2.5. United States
10.3. Asia-Pacific
10.3.1. Australia
10.3.2. China
10.3.3. India
10.3.4. Indonesia
10.3.5. Japan
10.3.6. Malaysia
10.3.7. Philippines
10.3.8. South Korea
10.3.9. Thailand
10.4. Europe, Middle East & Africa
10.4.1. France
10.4.2. Germany
10.4.3. Italy
10.4.4. Netherlands
10.4.5. Qatar
10.4.6. Russia
10.4.7. Saudi Arabia
10.4.8. South Africa
10.4.9. Spain
10.4.10. United Arab Emirates
10.4.11. United Kingdom

11. Competitive Strategic Window
11.1. Introduction
11.2. Competitive Strategic Window, by Infection
11.3. Competitive Strategic Window, by Type
11.4. Competitive Strategic Window, by Age Group
11.5. Competitive Strategic Window, by Geography

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AstraZeneca
13.2. Bavarian Nordic
13.3. Bayer AG
13.4. Bio Farma
13.5. Dynavax Technologies Corporation
13.6. Emergent BioSolutions, Inc.
13.7. GlaxoSmithKline plc
13.8. Merck & Co., Inc.
13.9. Pfizer Inc.
13.10. Sanofi S.A.
13.11. Seqirus USA Inc.
13.12. Serum institute of India Private Limited

14. Appendix
14.1. Discussion Guide
14.2. Edition Details
14.3. License Details
14.4. Pricing Details

LIST OF FIGURES
FIGURE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019 VS 2025 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019 VS 2025 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 8. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL RESPIRATORY DISEASE VACCINE MARKET, BY TYPE
FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2025 (USD MILLION)
FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE GROWTH , 2017-2025 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019 VS 2025 (USD MILLION)
FIGURE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019 VS 2025 (USD MILLION)
FIGURE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 17. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 18. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2025
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2025
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 24. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 25. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: 360IRESEARCH MARKET SHARE ANALYSIS

LIST OF TABLES
TABLE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2025 (USD MILLION)
TABLE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 16. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 17. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 18. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 19. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 20. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 21. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 22. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 23. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 24. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 25. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 26. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 27. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 28. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 29. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 30. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 31. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 32. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 33. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 34. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 35. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 36. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 37. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 38. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 39. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 40. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 41. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 42. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 43. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 44. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 45. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 46. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 47. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 48. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 49. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 50. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 51. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 52. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 53. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 54. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 55. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 56. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 57. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 58. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 59. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 60. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 61. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 62. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 63. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 64. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 65. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 70. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 71. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 72. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 73. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 74. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 75. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 76. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 77. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 78. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 79. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 80. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 81. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 82. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 83. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 84. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 85. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 86. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 87. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 88. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 89. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 90. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 91. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 92. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 93. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 94. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 95. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 96. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 100. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2017-2025 (USD MILLION)
TABLE 101. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 102. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2025 (USD MILLION)
TABLE 103. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: SCORES
TABLE 104. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BUSINESS STRATEGY
TABLE 105. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: PRODUCT SATISFACTION
TABLE 106. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: RANKING
TABLE 107. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: MERGER & ACQUISITION
TABLE 108. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 109. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 110. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: INVESTMENT & FUNDING
TABLE 111. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 112. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: EDITION DETAILS
TABLE 113. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: LICENSE DETAILS
TABLE 114. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: PRICING DETAILS
Note: Product cover images may vary from those shown
3 of 3
  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seqirus USA Inc.
  • Serum institute of India Private Limited
Note: Product cover images may vary from those shown
Adroll
adroll